PDC Pharma Strategy CEO, Penelope Przekop, comments on this at the FDA / Duke University-Margolis Institute for Health Policy public workshop, "Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches" on January 31st, 2024.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.